Toth Financial Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Toth Financial Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Hold	6,600	–	–	0.16%	120
2026 Q1	$1.25M	Buy	+6,600	New	+$1.15M	0.14%	121
2021 Q3	–	Sell	-2,800	Closed	-$497K	–	768
2021 Q2	$497K	Buy	+2,800	New	+$485K	0.08%	151

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Toth Financial Advisory's JAZZ Position: Q2 2026 in Review

Toth Financial Advisory held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 6,600 shares worth $1.59M. The position accounts for 0.16% of the portfolio, ranked #120.

Toth Financial Advisory first reported a position in JAZZ in Q2 2021 and has held it in 3 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Toth Financial Advisory held 6,600 shares of Jazz Pharmaceuticals worth $1.59M as of Q2 2026.
Toth Financial Advisory left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up 0.16% of Toth Financial Advisory's portfolio in Q2 2026, its #120 holding.
Toth Financial Advisory first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 3 quarters since.
641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.